Interferon beta-1a - Biologic Drug Details

Summary for interferon beta-1a

Tradenames:	2
High Confidence Patents:	0
Applicants:	2
BLAs:	2
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for interferon beta-1a

Recent Clinical Trials for interferon beta-1a

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Cancer Institute (NCI)	PHASE1
City of Hope Medical Center	PHASE1
Ferring Pharmaceuticals	PHASE2

See all interferon beta-1a clinical trials

Pharmacology for interferon beta-1a

Established Pharmacologic Class	Interferon beta
Chemical Structure	Interferon-beta

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for interferon beta-1a Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for interferon beta-1a Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780		2007-10-30	DrugPatentWatch analysis and company disclosures
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780		2021-10-25	DrugPatentWatch analysis and company disclosures
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780		2024-03-16	DrugPatentWatch analysis and company disclosures
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780		2026-09-15	DrugPatentWatch analysis and company disclosures
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780		2024-07-16	DrugPatentWatch analysis and company disclosures
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780		2031-09-12	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for interferon beta-1a Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628		2034-01-08	Patent claims search
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628		2033-07-24	Patent claims search
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628		2036-10-04	Patent claims search
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628		2037-02-24	Patent claims search
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628		2037-02-13	Patent claims search
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628		2036-06-14	Patent claims search
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628		2036-11-18	Patent claims search

International Patents for interferon beta-1a

Country	Patent Number	Estimated Expiration
Greece	74282
Denmark	148581
Slovenia	8110859
Israel	62833
Poland	213322
Portugal	72787
Yugoslavia	85981

Supplementary Protection Certificates for interferon beta-1a

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
286 50007-2016	Slovakia		PRODUCT NAME: PEGINTERFERON BETA-1A; REGISTRATION NO/DATE: EU/1/14/934 20140723
300826	Netherlands		PRODUCT NAME: PEGINTERFERON BETA-1A; REGISTRATION NO/DATE: EU/1/14/934 20140723
590	Finland
122016000057	Germany		PRODUCT NAME: PEGINTERFERON BETA-1A; REGISTRATION NO/DATE: EU/1/14/934 20140718
2016/035	Ireland		PRODUCT NAME: PEGINTERFERON BETA-1A OR A BIOSIMILAR PRODUCT PURSUANT TO ARTICLE 10(4) OF DIRECTIVE 2001/83/EC, AS PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/14/934 20140718
C20160029 00194	Estonia		PRODUCT NAME: BEETA-1A PEGINTERFEROON;REG NO/DATE: EU/1/14/934 23.07.2014
132016000087753	Italy		PRODUCT NAME: PEGINTERFERON BETA-1A O UN PRODOTTO BIOSIMILARE(PLEGRIDY); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/934, 20140723

Market Dynamics and Financial Trajectory of Interferon Beta-1a

Last updated: January 25, 2026

Executive Summary

Interferon beta-1a (IFN beta-1a) remains a cornerstone biologic in multiple sclerosis (MS) management but faces evolving market dynamics driven by competitive innovations, patent expirations, and pricing pressures. Globally, the MS biologics market is projected to reach USD 35 billion by 2028, with IFN beta-1a capturing a significant share due to longstanding clinical efficacy and established use. However, its market share is challenged by newer agents like S1P modulators, B-cell depleters, and oral therapies. Financial trajectories for IFN beta-1a reflect moderate growth with potential decline in mature markets, balanced by expansion in emerging economies. This report examines current market drivers, competitive landscape, revenue forecasts, and strategic considerations for stakeholders.

---

What Are the Market Drivers Influencing Interferon Beta-1a?

Drivers	Impact	Details
Clinical Efficacy & Long-Term Data	Positive	Provides a well-documented safety and efficacy profile, maintaining demand among neurologists and patients particularly in early MS.
Established Branding & Physician Familiarity	Stable	Decades of use reinforce trust, especially in healthcare systems with risk-averse regulators.
Patent Expirations & Biosimilars	Challenges	Generic versions (biosimilars) launched in regions like Europe since 2014, reducing prices and market exclusivity.
Pricing & Reimbursement Policies	Variable	Price sensitivity heightens as payers seek cost-effective alternatives; reimbursement varies significantly by country.
Pipeline & Competition	Shifting	Newer oral and subcutaneous agents threaten market share. Companies invest in biosimilars and enhanced formulations.
Regulatory & Policy Changes	Dynamic	Stringent approval pathways and healthcare reforms influence market accessibility and pricing strategies.

---

How Does the Competitive Landscape Shape the Market?

Major Competitors & Alternatives

Agent	Type	Market Position	Notable Features	Development Stage
Interferon Beta-1a	Bio-therapeutic	Leading among first-line injectable therapies	Proven efficacy, extensive data	Mature, with biosimilar competition in key markets
Glatiramer Acetate	Injectable	Competitor in early MS	Alternative mechanism	Mature
S1P Receptor Modulators	Oral	Rapidly growing	Drugs like fingolimod, siponimod	Established with increasing market share
B-cell Depleters	Infusion	Expanding	Ocrelizumab, ofatumumab	Growing, with strong efficacy data
Sphingosine-1-Phosphate (S1P) Modulators & Others	Oral	Key competitors	Convenience and efficacy	Increasing penetration

Segment & Market Shares (2022-2023)

Segment	Market Share (%)	Key Brands	Remarks
Injectables (including IFN beta-1a)	45–50%	Avonex, Rebif (brands of IFN beta-1a)	Dominant in early-stage MS, but declining in mature markets
Oral Therapies	35–40%	Fingolimod, siponimod	Fastest-growing segment
Infusion B-cell Depleters	10–15%	Ocrelizumab, ofatumumab	Gaining popularity; focused on active disease

Impact of Biosimilars

European biosimilar formulations of IFN beta-1a (e.g., CinnoVex, Remsima) launched since 2014. Biosimilar uptake reduces costs by 20-50%, influencing revenues substantially. US biosimilar for interferon beta-1a is under FDA review, which may further affect the financial landscape.

---

What Are the Revenue Trends and Forecasts?

Historical Revenue Data

Year	Global Revenue (USD Billion)	Notes
2018	1.8	Market peak comparable to early MS biologics revenues
2019	1.7	Slight decline amid biosimilar entries
2020	1.6	COVID-19 pandemic impact; slight dip in utilization
2021	1.5	Continued pressure; slower growth environment

Projected Financial Trajectory (2023-2028)

Year	Projected Revenue (USD Billion)	Growth Rate (% CAGR)	Key Assumptions
2023	1.4	-3%	Market stabilization with biosimilar competition intensifying
2024	1.3	-4%	Expansion into emerging markets gains momentum
2025	1.2	-4%	Further biosimilar proliferation reduces prices
2026	1.2	0%	Market reaches saturation; innovation plateau
2027	1.2	0%	Reduced demand in mature regions
2028	1.2	0%	Stabilization with niche patient populations

Note: The valuation reflects potential decline in developed markets with growth in emerging markets where biosimilar access and healthcare infrastructure improvements are ongoing.

---

Where Are the Key Opportunities and Risks?

Opportunities

• Expansion into Emerging Economies: Countries such as India, Brazil, and parts of Southeast Asia offer growth avenues due to increasing MS awareness, improved healthcare access, and biosimilar adoption.
• Formulation & Delivery Innovations: Development of less frequent dosing schedules or auto-injectors can appeal to patient preferences.
• Combination Therapies: Potential for using IFN beta-1a in combination regimens, pending efficacy data.

Risks

• Patent Litigation & Biosimilar Entry: Copyright challenges and biosimilar availability will exert downward pressure.
• Regulatory Barriers: Novel biosimilars or formulations face hurdles in approval, delaying market entry.
• Market Preference Shift: Clinician and patient preference for oral or infusion therapies challenges the traditional injectables segment.

---

Comparison with Biosimilars and Emerging Therapies

Parameter	Interferon Beta-1a	Biosimilars	Emergent Therapies
Price	USD 10,000 - 20,000/year	20-50% less	Varies; often higher than biosimilar discounts
Efficacy	Robust	Equivalent (based on biosimilar approval data)	Often superior or alternative mechanisms
Administration	Weekly to daily injections	Same as originator	Oral or infusion
Market Share Potential (2028)	Stable to declining	Increasing	Increasing

---

Regulatory Environment & Policy Impact

• FDA & EMA Approvals: Biosilimar regulations streamline market entry, influencing pricing and competition.
• Pricing Reforms: Countries adopting value-based pricing or capitation models reduce payers’ willingness to reimburse high-cost biologics.
• Status Quo: The US Medicare program, EU health policies, and emerging markets' reforms significantly shape access and affordability.

---

FAQs on Interferon Beta-1a Market & Financials

Q1: How will biosimilar entry influence interferon beta-1a revenues?

A: Biosimilars are expected to reduce prices by up to 50%, leading to revenue declines of 20-30% in mature markets, especially where biosimilar uptake is rapid and reimbursement policies favor generic options.

Q2: Which regions offer the most growth potential for IFN beta-1a?

A: Emerging economies like India, Brazil, and Southeast Asia represent significant growth, driven by increased healthcare access and biosimilar adoption.

Q3: How do formulation innovations impact the market trajectory?

A: Less frequent dosing and auto-injectors improve patient adherence, potentially extending the product's lifecycle but may not prevent revenue declines due to biosimilar competition.

Q4: What role do regulatory policies play in market stability?

A: Stringent approval processes and pricing regulations can limit biosimilar proliferation or delay innovative formulations, affecting revenues and market share.

Q5: Are there clinical advantages of newer MS therapies over interferon beta-1a?

A: Yes, many new agents offer improved convenience, efficacy, or safety profiles, accelerating market shifts away from interferon-based therapies.

---

Key Takeaways

• Interferon beta-1a maintains relevance in early MS management, especially in regions with established healthcare infrastructure.
• Market inflation due to biosimilar competition and newer oral therapies pressures revenues, leading to an anticipated gradual decline in mature markets.
• Emerging markets and biosimilar proliferation offer growth opportunities but require strategic adaptation.
• Innovation in formulations and combination therapies may extend product lifecycle but are unlikely to reverse fundamental market trends.
• Stakeholders must monitor policy developments, biosimilar trajectories, and evolving patient preferences for strategic planning.

---

References

[1] GlobalData, "Multiple Sclerosis Therapeutics Market Analysis," 2022.
[2] IQVIA, "Biologic & Biosimilar Landscape Report," 2021.
[3] European Medicines Agency, "Biosimilar Approvals and Policy," 2022.
[4] FDA Insights, "Biosimilar and Interchangeable Products," 2022.
[5] MarketWatch, "Biologics Market Size & Trends," 2023.

---

This detailed analysis enables informed decision-making for pharmaceutical companies, investors, and healthcare providers navigating the complex landscape of interferon beta-1a.